|
|
|
|
|
|
|
|
ESMO (website)
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
The ESMO-MCBS will be a dynamic tool and its criteria will be revised on a regular basis.
- Read the accompanying Press Release: ESMO Announces a Scale to Stratify the Magnitude of Clinical Benefit of Anti-Cancer Medicines
- Read the editorial in Annals of Oncology: Proven efficacy, equitable access and adjusted pricing of anti-cancer therapies: no ́sweetheart ́ solution by Josep Tabernero on behalf of the ESMO Executive Board
theLancet Oncology
abstract
Several new cancer medicines are of little clinical benefit to patients, suggests a new study by investigators from the European Society for Medical Oncology (ESMO). The investigators devised a “validated and reproducible” method to assess the magnitude of cancer medicines' clinical benefits—called the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS).
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.